TG THERAPEUTICS, INC. Proceeds from Issuance of Debt
TG THERAPEUTICS, INC. (TGTX) reported Proceeds from Issuance of Debt of $747.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-08-05
- TG THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2026-06-30 was $0.00.
- TG THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2026-03-31 was $747.66M.
- TG THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2025-12-31 was $0.00.
- TG THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- TG THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- TG THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2024 was $244.81M, a 879.26% increase from fiscal 2023.
- TG THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2023 was $25.00M.
- TG THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $747.66M 10-Q · filed 2026-08-05 | $747.66M derived: sum of 3 quarters · filed 2026-08-05 | $747.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $747.66M 10-Q · filed 2026-05-06 | $747.66M derived: sum of 2 quarters · filed 2026-05-06 | $747.66M derived: sum of 3 quarters · filed 2026-05-06 | $747.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $244.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $244.81M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $244.81M derived: sum of 2 quarters · filed 2026-02-27 | $244.81M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $244.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $244.81M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $25.00M 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $25.00M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $25.00M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $25.00M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $70.00M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |